ctDNA (Liquid Biopsy for MRD) in the Curative Setting

Arielle J Medford, MD

Mass General Cancer Center/Harvard Medical School

MATOS Breast Conference

March 28, 2025

Mass General Diferentiant Mass General Cancer Center

Mass General Brigham







- What is molecular residual disease (MRD)?
- How is MRD detected?
- What is the prognostic significance of MRD?
- Can we intervene on MRD?


- What is molecular residual disease (MRD)?
- How is MRD detected?
- What is the prognostic significance of MRD?
- Can we intervene on MRD?

Hematologic Malignancies




Circulating tumor DNA (ctDNA)






- What is molecular residual disease (MRD)?
- How is MRD detected?
- What is the prognostic significance of MRD?
- Can we intervene on MRD?

Types of MRD Assays






A. Medford et al, Clinical Cancer Research, 2023

- What is molecular residual disease (MRD)?
- How is MRD detected?
- What is the prognostic significance of MRD?
- Can we intervene on MRD?

MRD means a very poor prognosis – hazard ratio up to 50+, lead time to clinical recurrence 9-18 months



Coombes et al, CCR 2019


Shaw et al, JCO PO 2024


MRD detection & lead times to BC recurrence


Study	Assay	Cancer Type	# patients	Median Lead Time	Hazard Ratio (RFS)	Median f/u	Sensitivity	Specificity
Garcia-Murillas et al (2015)	dPCR	All subtypes	55	7.9 months	Single timepoint: 25.1 (95% CI 4.08-130.5) Serial: 12.0 (95% CI 3.36-43.07)	~2 years	Post-surgery: 50% Serial: 80%	96%
Olsson et al (2015)	dPCR	All subtypes	20	11 months	N/A	9.2 years	93%	100%
Garcia-Murillas et al (2019)	dPCR	All subtypes	Primary cohort: 101 Combined cohort: 144	Primary: 38.0 months Combined: 10.7 months	Primary: 16.7 (95% Cl 3.5-80.5, p < .001) Combined: 17.4 (95% Cl 6.3-47.8)	Primary: 35.5 months Combined: 36.3 months	88.4%	100%
Coombes et al (2019)	Signatera	All subtypes	49	8.9	Post-surgery: 11.8 (95% CI 4.3–32.5) Serial: 35.8 (95% CI 8.0– 161.3)	~2 years (study midpoint)	89%	100%
Parsons et al (2020)	Internal tumor- informed	HR+/HER2-	35	18.9 months	Post-surgery: 5.1 (95% CI 2.0–12.7] 1 year post surgery: 20.8 (95% CI 7.3–58.9)	7.1 years	Post-surgery: 23% 1-year: 19%	Post-surgery: 96% 1-year: 100%
Lipsyc-Sharf et al (2022)	RaDaR	HR+/HER2-	85	12.4 months	N/A	10.4	85.7%	97.4%

Medford et al, Clinical Cancer Research, 2023

- What is molecular residual disease (MRD)?
- How is MRD detected?
- What is the prognostic significance of MRD?
- Can we intervene on MRD?








Prospective interventional clinical trials in MRD and Breast Cancer

Trial ID/name/ disease/phase	Drug treatment	Primary end point	Trial eligibility: MEDª	Trial eligibility: scan required ^a	Sample size: ctDNA ⁺ patients in intervention arm ^b	Trial status	Biopharma sponsored	Geography
Breast cancer								
DARE NCT04567420 (ref. 73) Stage II–III ER*/HER2 ⁻ breast Phase II	Palbociclib + endocrine therapy	ctDNA positivity during surveillance Relapse-free survival	Landmark or surveillance	Yes, scan required	100 (target)	Recruiting	No	USA (13 states; 15 sites)
LEADER NCTO3285412 (ref. 74) Localized ER ⁺ /HER2 ⁻ breast Phase II	Ribociclib + endocrine therapy	ctDNA clearance	Landmark or surveillance	No	30 (target)°	Recruiting	No	Massachusetts (3 sites)
TRAK-ER NCTO4985266 (ref. 75) Early stage ER ⁺ /HER2 ⁻ breast Phase II	Palbociclib + fulvestrant	ctDNA positivity during surveillance Relapse-free survival	Landmark or surveillance	Yes, scan required after MED	1,100 (surveillance target) ^d	Recruiting	No	UK and France (36 sites)
TREAT ctDNA NCT05512364 (ref. 76) Early stage ER ⁺ /HER2 ⁻ breast Phase III	Elacestrant	Distant metastasis-free survival	Landmark or surveillance	Yes, scan required after MED	220 (target)	Recruiting	No	Global (>10 countries, 120 sites)
ZEST NCT04915755 (ref. 77) Stage I–III triple-negative breast or HR ⁺ /HER2 ⁻ breast with BRCA mutation Phase III	Niraparib	Treatment emergent adverse events Change in ECOG Performance Status	Post-op or landmark	No	43 (actual)	Discontinued	Yes	Global (>10 countries, 200 sites)
c-TRAK-TN NCT03145961 (ref. 78) Early stage triple-negative breast Phase II	Pembrolizumab	ctDNA positivity during surveillance ctDNA clearance	Landmark or surveillance		45 (actual) ⁷⁹	Complete	No	UK (17 sites)
ASPRIA NCT04434040 (ref. 80) Early stage triple-negative breast Phase II	Atezolizumab + sacituzumab govitecan	ctDNA clearance	Landmark	No	40 (actual)	Active, not recruiting	No	USA (5 states, 9 sites)


Medford, Carmeli, Ritchie et al, Nature Reviews Cancer, 2024

A new approach to MRD-based clinical trials



Medford, Carmeli, Ritchie et al, Nature Reviews Cancer, 2024

A standing platform for MRD-based clinical trials



Summary

- MRD indicates breast cancer is going to recur.
- Patients are able to access MRD tests today, but no therapies are approved to intervene. This is a key area of unmet clinical need.
- Innovative translational research is required to understand mechanisms of therapy resistance and optimal MRD interventional clinical trials.
- An overhaul of the MRD-based clinical trial infrastructure is needed (and underway) to improve patient access and study opportunities.

Thank you!

Mentorship

Dejan Juric Gaddy Getz Aditya Bardia

Science for America/Reversing Early Recurrence

Aparna Parikh Eric Lander Ariel Carmeli Alex Ritchie Kaitlin Browman Sarah Neely

Haber/Maheswaran Lab

Daniel Haber Shyamala Maheswaran Lecia Sequist Avanish Mishra

MGH Breast Cancer Team

Beverly Moy Laura Spring Steven Isakoff Seth Wander Leif Ellisen Jeff Peppercorn Amy Comander Doug Micalizzi Jennifer Shin Janice Kim **Rachel Abelman** Neelima Vidula Irene Kuter Sadhna Vora Charlie Dai

MRD Research & Nursing Team

Justine Knape Aylin Dedeoglu Laurie Brennan Michelle Trodella Lauren Scarpetti

LEADER Study Team

Zanta Ephrem Zack Smolar

Getz Lab Team thanks!